With regard to the clinical stage, the prognosis of E-cadherin-negative cancer patients was significantly poorer than that of E-cadherin-positive cancer patients with regard to overall survival (P=0.002) and disease-free interval (P=0.002) in stage II (Figures 2B and C). Here, CDH1 is linked to cancer.